Jeff Yass’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-320,100
| Closed | -$3.19M | – | 13150 |
|
|
2025
Q2 | $3.19M | Buy |
320,100
+177,200
| +124% | +$1.43M | ﹤0.01% | 4842 |
|
|
2025
Q1 | $853K | Sell |
142,900
-929,700
| -87% | -$6.83M | ﹤0.01% | 7656 |
|
|
2024
Q4 | $8.24M | Buy |
1,072,600
+1,050,700
| +4,798% | +$9.03M | ﹤0.01% | 2896 |
|
|
2024
Q3 | $224K | Sell |
21,900
-1,373,100
| -98% | -$20.9M | ﹤0.01% | 10240 |
|
|
2024
Q2 | $20.7M | Buy |
+1,395,000
| New | +$20M | ﹤0.01% | 1686 |
|
|
2024
Q1 | – | Sell |
-691,800
| Closed | -$7.58M | – | 12730 |
|
|
2023
Q4 | $7.58M | Buy |
691,800
+503,500
| +267% | +$4.99M | ﹤0.01% | 3033 |
|
|
2023
Q3 | $2.06M | Buy |
188,300
+135,600
| +257% | +$1.73M | ﹤0.01% | 5066 |
|
|
2023
Q2 | $698K | Buy |
52,700
+24,000
| +84% | +$342K | ﹤0.01% | 7528 |
|
|
2023
Q1 | $391K | Buy |
+28,700
| New | +$514K | ﹤0.01% | 9152 |
|
|
2022
Q3 | – | Sell |
-15,700
| Closed | -$323K | – | 13651 |
|
|
2022
Q2 | $323K | Buy |
15,700
+1,400
| +10% | +$33.2K | ﹤0.01% | 9383 |
|
|
2022
Q1 | $460K | Buy |
+14,300
| New | +$520K | ﹤0.01% | 9193 |
|
Other funds holding ITOS
Jeff Yass's ITOS Position: Q3 2025 in Review
Jeff Yass sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 144,080 shares — an estimated $1.44M sold.
Jeff Yass first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $3.58M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Jeff Yass reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Jeff Yass sold 144,080 iTeos Therapeutics shares in Q3 2025, an estimated $1.44M.
- Jeff Yass first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
- Jeff Yass's iTeos Therapeutics position peaked at $3.58M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.